Colleen Hanlon - 18 Mar 2026 Form 3 Insider Report for Brainsway Ltd. (BWAY)

Reporting relationship: VP of Medical Affairs
Issuer ticker: BWAY
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 16:03:11 UTC
Source filing: View source filing
Reporting owner signature: /s/ Colleen Hanlon

Key filing fact

Colleen Hanlon filed Form 3 for Brainsway Ltd. (BWAY) on 18 Mar 2026.

Key facts

This page summarizes Colleen Hanlon's Form 3 filing for Brainsway Ltd. (BWAY).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 16:03.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002119434 Primary reporting owner

Hanlon Colleen

Relationship: VP of Medical Affairs
Address: 16 HARTUM STREET, RAD TOWER, 14TH FLOOR, HAR HAHOTZVIM, JERUSALEM, ISRAEL
Signature: /s/ Colleen Hanlon
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BWAY holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 53,881
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BWAY holding Derivative

Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,000
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

This figure includes: (i) 20,381 ordinary shares and (ii) unvested restricted stock units ("RSUs"), with each RSU representing a contingent right to receive one ordinary share, as follows: (a) RSUs to receive 6,000 ordinary shares vesting in equal quarterly installments until November 1, 2026, (b) RSUs to receive 2,500 ordinary shares vesting in equal quarterly installments until Mach 5, 2028 and (c) RSUs to receive 25,000 ordinary shares with 6,250 vesting on March 10, 2027 and the remainder vesting in equal quarterly installments until March 10, 2030.

Footnote F3

Stock options were granted on March 5, 2024, with the remaining options to purchase 5,000 ordinary shares vesting in equal quarterly installments until March 5, 2028.

Footnote F4

The exercise price is NIS 11.17 per share